Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free LIPO Stock Alerts

Lipella Pharmaceuticals (LIPO) Competitors

Lipella Pharmaceuticals logo
$0.03 0.00 (0.00%)
As of 08/28/2026
Compare

LIPO vs. XAGE, WINT, ALVOW, APLMW, and ARAV

Should you buy Lipella Pharmaceuticals stock or one of its competitors? Lipella Pharmaceuticals's main competitors and comparable companies include Longevity Health (XAGE), Windtree Therapeutics (WINT), Alvotech (ALVOW), Apollomics (APLMW), and Aravive (ARAV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lipella Pharmaceuticals compare to Longevity Health?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Longevity Health (NASDAQ:XAGE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Longevity Health has a net margin of -682.67% compared to Lipella Pharmaceuticals' net margin of -988.83%. Longevity Health's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Longevity Health -682.67%N/A -261.90%

In the previous week, Lipella Pharmaceuticals had 1 more articles in the media than Longevity Health. MarketBeat recorded 1 mentions for Lipella Pharmaceuticals and 0 mentions for Longevity Health. Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Longevity Health'saverage media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Longevity Health Neutral

Lipella Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Longevity Health has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Lipella Pharmaceuticals has higher earnings, but lower revenue than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.28-$5.02M-$2.42N/A
Longevity Health$1.05M0.38-$10.37M-$3.49N/A

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 29.0% of Longevity Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Lipella Pharmaceuticals beats Longevity Health on 8 of the 12 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Windtree Therapeutics?

Windtree Therapeutics (NASDAQ:WINT) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

In the previous week, Lipella Pharmaceuticals had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Lipella Pharmaceuticals and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Lipella Pharmaceuticals Neutral

29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Windtree Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

Windtree Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Windtree Therapeutics' return on equity of -207.34% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

Windtree Therapeutics has higher earnings, but lower revenue than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Lipella Pharmaceuticals$536.36K0.28-$5.02M-$2.42N/A

Summary

Windtree Therapeutics beats Lipella Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Alvotech had 2 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 3 mentions for Alvotech and 1 mentions for Lipella Pharmaceuticals. Alvotech's average media sentiment score of 0.38 beat Lipella Pharmaceuticals' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lipella Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alvotech has higher revenue and earnings than Lipella Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.95MN/AN/AN/AN/A
Lipella Pharmaceuticals$536.36K0.28-$5.02M-$2.42N/A

Alvotech has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Alvotech's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Alvotech beats Lipella Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 1.87 beat Lipella Pharmaceuticals' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Very Positive
Lipella Pharmaceuticals Neutral

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Apollomics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Apollomics' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

Apollomics has higher revenue and earnings than Lipella Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Lipella Pharmaceuticals$536.36K0.28-$5.02M-$2.42N/A

Summary

Apollomics beats Lipella Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Aravive?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Lipella Pharmaceuticals had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Lipella Pharmaceuticals and 0 mentions for Aravive. Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Aravive Neutral

Aravive has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Aravive's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Aravive N/A N/A N/A

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aravive has lower revenue, but higher earnings than Lipella Pharmaceuticals. Aravive is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.28-$5.02M-$2.42N/A
AraviveN/AN/AN/A-$0.90N/A

Summary

Aravive beats Lipella Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Lipella Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIPO vs. The Competition

Export
MetricLipella PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$151K$3.94B$7.18B$12.88B
Dividend YieldN/A3.61%2.54%11.27%
P/E Ratio-0.0111.68273.1725.45
Price / Sales0.281,408.89638.13103.78
Price / CashN/A44.0628.7436.03
Price / Book0.0216.9211.086.36
Net Income-$5.02M-$22.74M$3.48B$349.79M
7 Day PerformanceN/A-0.13%0.21%-0.48%
1 Month PerformanceN/A11.45%7.75%4.17%
1 Year PerformanceN/A55.66%24.68%15.11%

Lipella Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIPO
Lipella Pharmaceuticals
N/A$0.03
flat		N/AN/A$151K$536.36KN/A4
XAGE
Longevity Health
N/A$0.22
-19.4%		N/A-91.2%$397K$1.05MN/A14
WINT
Windtree Therapeutics
N/A$0.00
-50.0%		N/AN/A$4KN/AN/A30
ALVOW
Alvotech
N/A$0.38
-5.0%		N/AN/A$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-16.7%		N/A+79.5%$0.00$8.50MN/A59

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LIPO) was last updated on 8/31/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel